跳至主要内容
临床试验/NCT00768742
NCT00768742撤回不适用

Clinical Study to Assess the Safety and Effectiveness of VizAblate(tm) Intrauterine Ultrasound-guided RF Ablation (IUUSgRFA) of Submucosal and Intramural Uterine Fibroids on the Reduction of Pictorial Blood Loss Assessment Scores

Gynesonics6 个研究点 分布在 1 个国家开始时间: 2008年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
6
主要终点
Menstrual bleeding as measured by the Pictorial Blood Loss Assessment Chart (PBLAC)

研究概览

简要总结

The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Pre-menopausal
  • Regular, consistent menstrual cycles
  • Serum progesterone > 6 ng/ml (19 nmol/L)
  • 2 months history of PBLAC score of 150-500
  • Maximum of 4 type I, type II, or intramural fibroids
  • Patient is at low risk for cervical cancer
  • Hemoglobin > 6 g/dl
  • Not at risk for pregnancy
  • No desire for future fertility
  • Willing and able to complete the follow-up requirements outlined in the study design section of the protocol
  • Willing to sign a consent form

排除标准

  • Subserosal fibroids.
  • Any fibroid that obstructs access to the endometrial cavity
  • FSH > 20 IU/L
  • Pregnancy
  • Evidence of disorders of hemostasis
  • Use of GnRH agonist or depomedroxyprogesterone acetate or other implantable or injectable progestin and/or estrogen
  • SERMS/SPRMS within the last 6 months
  • Current use of any IUD or use of Mirena IUS within the last 3 months
  • Gynecological malignancy or hyperplasia
  • Known/suspected abdominal/pelvic cancer
  • Active pelvic infection (e.g., active salpingitis or other pelvic inflammatory disease)
  • Adenomyosis
  • Previous surgical or ablative treatment for fibroids or menorrhagia
  • Previous uterine artery embolization or occlusion
  • Patient on anti-coagulation therapy
  • Needing emergency surgery to treat fibroid symptoms
  • Concomitant intrauterine polyps.
  • Major medical or psychiatric illness affecting general health or patient's ability to comply with follow-up schedule or provide valid patient self-assessment data
  • Contraindication to MRI
  • Allergy to contrast media
  • Mild renal insufficiency or worse
  • Known renal disease
  • Uncontrolled hypertension lasting 2 years or more
  • Uterine size > 10 weeks or 10 cm from ectocervix to fundus.

结局指标

主要结局

Menstrual bleeding as measured by the Pictorial Blood Loss Assessment Chart (PBLAC)

时间窗: Baseline, 3 mo, 6 mo, 9 mo, 12 mo

次要结局

  • Quality of Life questionnaires(Baseline, 3 mo, 6 mo, 9 mo, 12 mo)
  • Rate of surgical reintervention(12 mo)
  • Adverse events(At time of discharge, 7-14 days, 3 mo, 6 mo, 9 mo, 12 mo.)
  • Subject tolerance of procedure rated via analog visual scale(Discharge)
  • Fibroid dimension and non-perfused volume(Baseline, 1 day, 3 mo, 6 mo, 9 mo, and 12 mo)
  • Pregnancy and pregnancy-related complications(3 mo, 6 mo, 9 mo, and 12 mo)
  • Time required to return to normal daily activity(7-14 days)

研究者

发起方
Gynesonics
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验